«

»

Jun 16

Agilent Technologies announces new lab informatics suite at Pittcon 2010 Agilent Systems Inc tadalafil.

Agilent Technologies announces new lab informatics suite at Pittcon 2010 Agilent Systems Inc tadalafil . today announced the next at Pittcon 2010: a major new laboratory informatics suite; a seafood species verification lab-on-a-chip program; a significant food testing lab collaboration; a high-performance transportable GC/MSD; a high-throughput single quadrupole liquid chromatograph/mass spectrometer . The company announced an instrument to facilitate third-party software program also control for Agilent LCs. OpenLAB is scalable, open architecture predicated on industry open standards. Agilent OpenLAB includes three integrated solutions: OpenLAB Chromatography Data Program , OpenLAB Electronic Lab Notebook , and OpenLAB Enterprise Content material Manager . Agilent OpenLAB ELN makes the protection and efficiencies of electronic lab notebooks accessible to a wider selection of labs, including those performing routine analytical work in areas such as hydrocarbon processing, environmental evaluation, pharmaceutical food protection, and forensics. Agilent OpenLAB ECM is normally a protected, central repository enabling customers to capture, manage, talk about, archive, and re-make use of any data in most file formats. Agilent also introduced the Device Control Framework , a software component rendering it faster and much easier for third-party software to regulate Agilent liquid chromatography systems in chromatographic data systems or workstations. Based on new standard instrument motorists from Agilent, ICF eliminates much of your time and effort and delay associated with software designers using low-level device control codes to write their own native drivers. ICF is open to software developers at no cost. Fish Species Verification The Agilent Fish Species Identification technique speeds and simplifies the usage of DNA to identify fish species in foods. The Agilent Fish Species Identification method makes this accurate technique feasible for highly routine verification of seafood labeling and detecting species substitutions. The operational system uses an Agilent DNA Fish Species ID Ensemble with an Agilent 2100 Bioanalyzer lab-on-a-chip program, and specialized RFLP Decoder Software. The DNA evaluation method is based on polymerase chain reaction-restriction fragment size polymorphism . The method is far more robust and accurate than existing protein-based tests, and also reduces enough time needed to confirm species in food from days to hours. Related StoriesCologuard stool DNA test: A precise screening choice for Alaska Native people who have colorectal cancerResearchers reveal how billed gold nanoparticles influence structure of DNA and RNACancer DNA in individual's bloodstream could help deliver personalized treatment for liver cancer Major Food Lab Collaboration Agilent and the National Center for Food Protection and Technology today announced they have entered right into a collaboration to build up new scientific methods for food testing, with the goal of solving a wide range of persistent complications facing global food supply chains. Within the collaboration, Agilent shall equip the NCFST laboratory in Summit-Argo, Ill., with a thorough assortment of the most recent analytical chemistry and life science instrumentation including: a Model 7890 gas chromatograph; a Model 5975B gas chromatograph/mass spectrometer ; a Model 7000B triple quadrupole GC/MS; a Model 1290 Infinity ultra high-performance liquid chromatograph ; a Model 6400 triple quadrupole LC/MS; a Model 6500 Accurate Mass quadrupole time-of-flight MS; a Model 7700 inductively coupled-plasma MS; and a Model 2100 Bioanalyzer, which is a lab-on-a-chip system set up to analyze DNA in fish samples. Using proprietary LTM technology, Agilent has developed the 5975T LTM GC/MS to be smaller, more rugged and to consume less power than in-laboratory GC/MSD instruments, yet capable of the same high-quality overall performance in the field. The 5975T LTM GC/MSD is particularly well-suited for chemical warfare analysis, 1st responders, and military and homeland protection officials who need fast and extremely accurate outcomes in the field. Additional out-of-laboratory applications include meals safety testing and environmental monitoring. Higher-Throughput Solitary Quad LC/MS In addition, Agilent released the Agilent 6150B Series solitary quadrupole liquid chromatograph/mass spectrometer , a new generation of the workhorse instrument. The 6150B Series has considerably higher sample throughput and delivers unmatched performance in the single quad LC/MS category. To match the quickness of fast chromatography, including ultra high-efficiency liquid chromatography such as the Agilent 1290 Infinity platform, the Agilent 6150B Series can scan at 10,000 amu per second, while maintaining outstanding data quality. This is important to confirm identification of the right compound in the complicated reaction mixtures, such as for example those within drug discovery synthesis.

Agensys, Seattle Genetics to co-develop second antibody-drug conjugate for multiple stable tumors Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-centered Astellas Pharma Inc. , today announced that Seattle Genetics offers exercised a choice to co-develop another antibody-drug conjugate under the companies’ existing ADC collaboration contract. The ADC, known as ASG-22Me personally , targets the Nectin-4 antigen, which is definitely expressed on multiple solid tumors. During the first quarter of 2011, Agensys submitted an investigational new drug application to the U.S. Food and Medication Administration for a stage I trial of ASG-22ME. Seattle Genetics and Agensys are co-developing another ADC referred to as ASG-5ME also, which happens to be in phase I scientific trials for pancreatic and prostate cancer. Related StoriesRUCDR Infinite Biologics awarded $6 million grant from NINDSGenetics and competition influence individuals' response to anticancer medication treatmentsBrodalumab therapy achieves 100 percent reduction in psoriasis symptoms’ASG-22ME is the second ADC we are co-developing under our collaboration with Agensys/Astellas, and the fifteenth ADC using Seattle Genetics’ technology in clinical advancement across both our internal pipeline and collaborator applications,’ stated Eric L. Dobmeier, Chief Business Officer of Seattle Genetics. ‘The improvement we and Agensys/Astellas are making demonstrates the synergy of combining Seattle Genetics’ innovative, industry-leading ADC technology with Agensys’ proprietary tumor targets and antibodies to build up potential new remedies for patients with tumor.’ ‘Both of these co-development applications with Seattle Genetics, coupled with other internal programs such as our AGS-16M8F ADC that’s in a phase I trial for renal cell carcinoma, demonstrate our commitment to ADCs and the strength of our developing oncology pipeline,’ said Sef Kurstjens, M.D., Ph.D., President and CEO of Agensys. ‘We look forward to continuing our productive and strong collaboration with Seattle Genetics.’.